Effects of leukapheresis protocol, cell processing and cryopreservation on the generation of monocyte-derived DC for immune therapy

Cytotherapy

Volumn 5, Issue 1, 2003, Pages 31-39

  Tazbirkova, A ^a,b   Okai, M ^a,b   Horley, D C ^b   Crough, T M ^a,b   Maksoud, A ^a   Nieda, M ^d   Nicol, Andrew ^a,b,c  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Cellular immune therapy; Leukapheresis; Monocyte derived dendritic cells

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ADULT; ARTICLE; AUTOMATION; BIOMEDICAL TECHNOLOGY ASSESSMENT; CELL ADHESION; CELL COMPOSITION; CELL COUNT; CELL DIFFERENTIATION; CELL MANIPULATION; COMPARATIVE STUDY; COMPUTER PROGRAM; CONTROLLED STUDY; COST; COST CONTROL; CRYOPRESERVATION; DENDRITIC CELL; DENSITY GRADIENT CENTRIFUGATION; DEPLETION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERMETHOD COMPARISON; LEUKAPHERESIS; LYMPHOCYTE; MONOCYTE; MONONUCLEAR CELL; PROCESSING; SPECTROSCOPY; THROMBOCYTE;

EID: 0037241496     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/14653240310000056     Document Type: Article

References (20)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
2. Brossart P, Wirths S, Stuhler G et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000;96:3102-8.
3. Nouri-Shirazi M, Banchereau J, Bell D et al. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol 2000;165:3797-803.
4. Nouri-Shirazi M, Banchereau J, Fay J et al. Dendritic cell based tumor vaccines. Immunol Lett 2000;74:5-10.
5. Chakraborty NG, Sporn JR, Tortora AF et al. Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting-cell-based vaccine in melanoma. Cancer Immunol Immunother 1998;47:58-64.
6. Thurner B, Haendle I, Roder C et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669-78.
7. Schuler-Thurner B, Dieckmann D, Keikavoussi P et al. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1 + melanoma patients by mature monocyte-derived dendritic cells. J Immunol 2000;165:3492-6.
8. Panelli MC, Wunderlich J, Jeffries J et al. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother 2000;23:487-98.
9. Wen YJ, Ling M, Bailey-Wood R et al. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin Cancer Res 1998;4:957-62.
10. Cull G, Durrant L, Stainer C et al. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma. Br J Haematol 1999;107:648-55.
11. Lim SH, Bailey-Wood R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int J Cancer 1999;83:215-22.
12. Murphy G, Tjoa B, Ragde H et al. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996;29:371-80.
13. Tjoa BA, Simmons SJ, Bowes VA et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998;36:39-44.
14. Tjoa BA, Lodge PA, Salgaller ML et al. Dendritic cell-based immunotherapy for prostate cancer. CA Cancer J Clin 1999;49:117-28, 165.
15. Holtl L, Rieser C, Papesh C et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 1999;161:777-82.
16. Morse MA, Deng Y, Coleman D et al. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 1999;5:1331-8.
17. Thurner B, Roder C, Dieckmann D et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 1999;223:1-15.
18. Wilke R, Brettell M, Prince HM et al. Comparison of COBE Spectra software Version 4.7 PBSC and Version 6.0 auto PBSC program. J Clin Apheresis 1999;14:26-30.
19. Lewalle P, Rouas R, Lehmann F et al. Freezing of dendritic cells, generated from cryopreserved leukaphereses, does not influence their ability to induce antigen-specific immune responses or functionally react to maturation stimuli. J Immunol Methods 2000;240:69-78.
20. Reddy A, Sapp M, Feldman M, Subklewe M et al. A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells. Blood 1997;90:3640-6.